JP6326563B2 - β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 - Google Patents

β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 Download PDF

Info

Publication number
JP6326563B2
JP6326563B2 JP2015501032A JP2015501032A JP6326563B2 JP 6326563 B2 JP6326563 B2 JP 6326563B2 JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015501032 A JP2015501032 A JP 2015501032A JP 6326563 B2 JP6326563 B2 JP 6326563B2
Authority
JP
Japan
Prior art keywords
bcp
mice
pcp
shows
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015501032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510926A (ja
JP2015510926A5 (enExample
Inventor
アナヴィ−ゴッファー，シャロン
ゲルチュ，ユルク
Original Assignee
アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド
アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド
ネイプロムド バイオファーマシューティカルズ ゲーエムベーハー
ネイプロムド バイオファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド, アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド, ネイプロムド バイオファーマシューティカルズ ゲーエムベーハー, ネイプロムド バイオファーマシューティカルズ ゲーエムベーハー filed Critical アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド
Publication of JP2015510926A publication Critical patent/JP2015510926A/ja
Publication of JP2015510926A5 publication Critical patent/JP2015510926A5/ja
Application granted granted Critical
Publication of JP6326563B2 publication Critical patent/JP6326563B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015501032A 2012-03-19 2013-03-19 β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 Expired - Fee Related JP6326563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612411P 2012-03-19 2012-03-19
US61/612,411 2012-03-19
PCT/IB2013/052182 WO2013140342A1 (en) 2012-03-19 2013-03-19 Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists

Publications (3)

Publication Number Publication Date
JP2015510926A JP2015510926A (ja) 2015-04-13
JP2015510926A5 JP2015510926A5 (enExample) 2016-05-12
JP6326563B2 true JP6326563B2 (ja) 2018-05-23

Family

ID=49221922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501032A Expired - Fee Related JP6326563B2 (ja) 2012-03-19 2013-03-19 β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療

Country Status (4)

Country Link
US (4) US20150051299A1 (enExample)
EP (1) EP2827846B1 (enExample)
JP (1) JP6326563B2 (enExample)
WO (1) WO2013140342A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140342A1 (en) 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
EP3265081A4 (en) 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP6397792B2 (ja) * 2015-04-10 2018-09-26 ポッカサッポロフード＆ビバレッジ株式会社 飲料
US20190070124A1 (en) * 2016-03-04 2019-03-07 Sharon Anavi-Goffer Compositions of cb2 receptor selective agonists for treatment of mental disorders
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
US20190241962A1 (en) * 2016-10-02 2019-08-08 Sharon Anavi-Goffer Genetic susceptibility diagnosis and treatment of mental disorders
US20230200435A1 (en) * 2020-03-10 2023-06-29 Kinki University Caryophyllene-containing agent or composition and various applications thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US20070154534A1 (en) * 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
WO2005121140A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
MX2007002116A (es) * 2004-10-01 2007-10-16 Ache Lab Farmaceuticos Sa Uso de cariofilinas en la fabricacion de medicamentos y tratamiento de condiciones corporales de inflamacion y dolor inflamatorio.
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
DK1903866T3 (en) * 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
BRPI0711064A2 (pt) * 2006-04-27 2011-08-23 Solvay Pharm Gmbh composições farmacêuticas compreendendo moduladores do receptor de canabinóides cbx e moduladores do canal de potássio
CA2688570A1 (en) * 2007-05-31 2008-12-04 F.P.L. Pharma Inc. Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
KR20110073653A (ko) 2009-12-24 2011-06-30 충북대학교 산학협력단 4-ｏ-메틸호노키올을 유효 성분으로 함유하는 항-불안 예방 및 치료용 의약 조성물
WO2013140342A1 (en) 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
WO2014170902A1 (en) 2013-04-17 2014-10-23 Ariel - University Research And Development Company, Ltd. Cb2 receptor ligands for the treatment of psychiatric disorders
US20190241962A1 (en) 2016-10-02 2019-08-08 Sharon Anavi-Goffer Genetic susceptibility diagnosis and treatment of mental disorders
EP3558281A4 (en) 2016-12-15 2020-07-08 Sharon Anavi-Goffer TREATMENT OF MENTAL DISORDERS, MOVEMENT AND BEHAVIOR

Also Published As

Publication number Publication date
WO2013140342A1 (en) 2013-09-26
US20150051299A1 (en) 2015-02-19
US11612572B2 (en) 2023-03-28
EP2827846B1 (en) 2020-08-12
EP2827846A1 (en) 2015-01-28
US20170151182A1 (en) 2017-06-01
EP2827846A4 (en) 2015-10-07
JP2015510926A (ja) 2015-04-13
US20230218540A1 (en) 2023-07-13
US20200261374A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP6326563B2 (ja) β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療
JP7066627B2 (ja) タンニン酸を含有する組成物及びその使用
CA2923685C (en) Application of r-ketamine and salt thereof as pharmaceuticals
US20190070124A1 (en) Compositions of cb2 receptor selective agonists for treatment of mental disorders
AU2015341458B2 (en) Methods for treatment of cognitive decline
TWI638654B (zh) 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物
WO2019109300A1 (en) Improved enrichment methods for preparing tannic acid compositions
CN118267382A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
CA3221395A1 (en) Methods and compositions for treating seizure disorders in pediatric patients
TWI686192B (zh) 含有鞣酸的組合物及其用途
TWI717576B (zh) 用以製備鞣酸組成物之改良精製純化方法
Smith Legalising medical cannabis in Australia.
KR20210135834A (ko) 헤스페리딘을 유효성분으로 함유하는 외상 후 스트레스장애 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20150519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171005

R150 Certificate of patent or registration of utility model

Ref document number: 6326563

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R313633

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees